Aquestive Therapeutics Capital Expenditures (CapEx) Growth & History (AQST)

Aquestive Therapeutics's capital expenditures (capex) was $562,000 for fiscal 2025.

View full Aquestive Therapeutics company overview

Aquestive Therapeutics annual capital expenditures (capex) history

Aquestive Therapeutics annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20252025-12-31$562,000$403,000+253.46%
20242024-12-31$159,000−$836,000−84.02%
20232023-12-31$995,000−$29,000−2.83%
20222022-12-31$1.0M$111,000+12.16%
20212021-12-31$913,000$396,000+76.60%
20202020-12-31$517,000−$146,000−22.02%
20192019-12-31$663,000−$1.2M−63.65%
20182018-12-31$1.8M−$244,000−11.80%
20172017-12-31$2.1M

Aquestive Therapeutics capital expenditures (capex) trends

Over the last five fiscal years, Aquestive Therapeutics's capital expenditures (capex) increased from $517,000 to $562,000, a change of $45,000. The latest reported quarter, Q2 2026, shows $212,000.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Aquestive Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about AQST yet. Start the conversation.

Write the first post